Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD by Hara Akinori et al.
Clinical and Pathological Significance of
Autoantibodies to Erythropoietin Receptor in
Type 2 Diabetic Patients With CKD
著者 Hara Akinori, Furuichi Kengo, Koshino Akihiko,
Yasuda Haruka, Tran Trang Thi Thu, Iwata
Yasunori, Sakai Norihiko, Shimizu Miho, Kaneko
Shuichi, Nakamura Hiroyuki, Wada Takashi
著者別表示 原 章規, 古市 賢吾, 岩田 恭宜, 坂井 宣彦, 清水










Creative Commons : 表示 - 非営利 - 改変禁止
http://creativecommons.org/licenses/by-nc-nd/3.0/deed.ja
 1 
Clinical and pathological significance of autoantibodies to erythropoietin receptor 
in type 2 diabetic patients with chronic kidney disease 
 
Akinori Hara, MD, PhD1, 2, Kengo Furuichi, MD, PhD1, 3, Akihiko Koshino, MD1, 3, 
Haruka Yasuda, MS 4, Trang Thi Thu Tran, MD4, Yasunori Iwata, MD, PhD1, 3, Norihiko 
Sakai, MD, PhD1, 3, Miho Shimizu, MD, PhD1, 3, Shuichi Kaneko, MD, PhD3, Hiroyuki 
Nakamura, MD, PhD2, Takashi Wada, MD, PhD1, 4 
 
1Division of Nephrology, Kanazawa University Hospital, 2Department of Environmental 
and Preventive Medicine, 3Department of Disease Control and Homeostasis 
and 4Department of Nephrology and Laboratory Medicine, Faculty of Medicine, 
Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 
Kanazawa, Japan 
 
Correspondence: Takashi Wada 
Division of Nephrology, Kanazawa University Hospital, Department of Nephrology and 
Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and 
Health Sciences, Kanazawa University 
 2 
13-1 Takara-machi, Kanazawa 920-8641, Japan 




A running headline: Anti-EPOR antibodies in diabetic nephropathy 
 
Word Counts: 
Abstract word count: 218 words 






Introduction: We examined the impact of autoantibodies to the erythropoietin receptor 
(EPOR) in type 2 diabetic patients with chronic kidney disease (CKD).  
Methods: One hundred and twelve Japanese patients with type 2 diabetes who had CKD 
were enrolled in this study and followed for a mean of 45 months. Sera from those 
patients were screened for anti-EPOR antibodies using enzyme-linked immunosorbent 
assays. Results: Anti-EPOR antibodies were detected in 26 patients (23%). Anti-EPOR 
antibodies were associated with low hemoglobin concentrations and decreased renal 
function. In patients with biopsy-proven diabetic nephropathy, anti-EPOR antibodies 
were associated with increased levels of interstitial inflammation. A decrease in renal 
function was observed more frequently in patients with antibodies than in patients 
without antibodies, and the presence of the antibodies as well as well-known clinical 
parameters, including proteinuria and low glomerular filtration rate, was a significant 
risk factor for end-stage renal disease (ESRD). In human tubular epithelial cells, HK-2, 
immunoglobulin G fractions with anti-EPOR antibodies upregulated the expression of 
monocyte chemoattractant protein-1 mRNA under high glucose concentration.  
Conclusion: The present study suggests that anti-EPOR antibodies might be involved in 
the progression of renal lesions, as well as in the impaired erythropoiesis in type 2 
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diabetic patients with CKD. Further, the presence of anti-EPOR antibodies may be an 
additional predictor for ESRD in type 2 diabetes. 
 






Diabetes and its complications are major causes of morbidity and mortality in 
most countries.1 Among diabetic complications, nephropathy occurs in 20–40% of 
patients during the course of their disease.2 Although kidney disease attributable to 
diabetes is referred to as diabetic nephropathy or diabetic kidney disease, diabetes and 
various kidney diseases have become common chronic conditions.3 Thus, the 
prevalence of chronic kidney disease (CKD) is increasing in proportion to the increase 
in the prevalence of diabetes, and it has been predicted to continue to increase in the 
future.4 Of note, diabetes is a risk factor of cardiovascular disease and death, and CKD 
further increases these risks.5-8 Anemia is observed commonly in diabetic patients with 
CKD and is involved in the increased risk for the progression of kidney disease and 
cardiovascular mortality and morbidity.7, 9-11 
Anemia in diabetic patients with CKD may result from one or more 
mechanisms. Among these, the major causes are iron and erythropoietin (EPO) 
deficiencies and hyporesponsiveness to the action of EPO.11 In view of EPO 
hyporesponsive anemia, we previously detected and reported autoantibodies to the EPO 
receptor (EPOR) as a possible cause of anemia with erythroid hypoplasia.12 In this study, 
unexpectedly, these antibodies were detected even in diabetic patients with CKD, 
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although their clinical significance remains to be investigated.12 In addition, a recent 
study revealed that anti-EPOR antibodies were associated with overall disease activity 
and decline of renal function in patients with systemic lupus erythematosus.13 
These results prompted us to examine the clinical and pathological impact of 
anti-EPOR antibodies in type 2 diabetic patients with CKD. We found that anti-EPOR 
antibodies are detected in a subset of patients, are associated with renal lesions, and that 





One hundred and twelve type 2 diabetic patients who had been diagnosed as having 
CKD and followed at Kanazawa University Hospital between 1989 and 2014 were 
included in this study. The mean follow-up period was 45.3 ± 47.4 months. Patients 
with secondary diabetes, renal transplantation, or dialysis were excluded. Among the 
enrolled patients, 51 underwent a renal biopsy. A diagnosis of diabetic nephropathy was 
confirmed by histological characteristics using renal biopsy specimens including light 
microscopy, electron microscopy, and immunofluorescence examination. Renal biopsy 
was performed for the precise diagnosis of renal lesions with the consent of each patient. 
All blood samples were obtained after the patients had given their written informed 
consent at admission for the renal biopsy or for work up and treatment of the disease. 
The study protocol adhering to the Declaration of Helsinki was approved by the medical 
ethics committee of Kanazawa University. Of note, 8 healthy individuals in addition to 
40 ones were included as healthy controls, and as a result, anti-EPOR antibodies were 
not detected in serum samples from these subjects.12  
 
Clinical features and routine laboratory tests 
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Demographic and clinical features were evaluated for each enrolled patient. Baseline 
clinical and laboratory findings including the use of angiotensin-converting enzyme 
(ACE) inhibitors, angiotensin II receptor blockers (ARBs) and erythropoiesis 
stimulating agents (ESAs) were extracted from medical records. Twenty-four hour 
urinary protein excretion, serum creatinine, estimated glomerular filtration rate (eGFR), 
HbA1c, body mass index (BMI), systolic and diastolic blood pressure, total cholesterol, 
hemoglobin (Hb), iron, total iron binding capacity (TIBC), ferritin, and C-reactive 
protein (CRP) were used as baseline clinical parameters at admission. eGFR for 
Japanese patients was calculated using the following equation: eGFR (mL/min/1.73 m2) 
= 194 × serum creatinine-1.094 × age-0.287 (if female, × 0.739).14 HbA1c levels were 
presented as National Glycohemoglobin Standardization Program values according to 
the recommendations of the Japan Diabetic Society15 and International Federation of 
Clinical Chemistry values. Autoantibodies against glutamic acid decarboxylase (GAD) 
were measured by a commercial quantitative enzyme-linked immunosorbent assay 
(ELISA; SRL, Inc., Tokyo, Japan). 
 
Detection of autoantibodies to EPOR 
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Anti-EPOR antibodies were detected by ELISA as described previously.12 Briefly, 
polyvinyl 96-well microtitration plates (Nunc International, Tokyo, Japan) were coated 
with recombinant human EPOR (R & D Systems, Minneapolis, MN, USA) at 5 μg/mL 
diluted in 0.2 M NaHCO3 buffer at 4 °C for 24 h. The remaining free-binding sites were 
blocked with 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) at 
4 °C. After the plates were washed with Tween 20-Tris-buffered saline, the samples 
were added in duplicate at 1:1,000 dilution to 1% BSA in PBS for 20 h at 4 °C. The 
plates were washed 4 times with the same buffer and incubated with goat anti-human 
Ig-conjugated with horseradish peroxidase (Millipore, Temecula, CA, USA) at 1:5,000 
dilution for 1.5 h at room temperature. The substrate tetramethylbenzidine (KPL, 
Gaithersburg, MD, USA) was added and the reaction was stopped by the addition of 2 
N sulfuric acid. The optical density at 450 nm (OD450) was determined by an automatic 
plate reader and the sample was considered to be antibody-positive when the ratio of 
patient serum OD450 to that of normal control sera was ≥2.4. This cutoff OD value was 
determined by a preliminary analysis using a receiver operating characteristic curve to 
predict, sensitively and specifically, renal outcome among the enrolled type 2 diabetic 
patients with a positive OD value ≥ 1.512 (data not shown). 
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Purification of immunoglobulin G fractions 
Sera from patients and control subjects were clarified by centrifugation at 1,500 × g for 
20 min (500 µL) and filtration through 0.45 µm filters (Millipore, County Cork, Ireland). 
Immunoglobulin (Ig) G fractions were prepared using a MAb Trap Kit (GE Healthcare, 
Tokyo, Japan) according to the manufacturer’s instructions. Purified IgG fractions were 




Renal biopsy specimens were prepared for light microscopic examination as described 
previously.7 In brief, patients’ samples were fixed in 10% phosphate-buffered formalin 
(pH 7.2), embedded in paraffin, and sliced into 4-µm sections. These specimens were 
stained with hematoxylin and eosin, periodic acid Schiff (PAS) reagent, Mallory-Azan, 
and periodic acid silver methenamine, and were examined under a light microscope. 
The severity of diffuse lesions of glomeruli was graded on a scale of 0 to 4 as described 
previously: grade 0, all glomeruli appear normal; grade 1, local lesions present within 
each glomerulus and focal lesions present within the kidney; grade 2, mesangial 
thickening is diffuse within the glomerulus and generalized throughout the kidney; 
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grade 3, capillary lumina are narrowed and obliterated only locally; and grade 4, the 
lumen is generally narrowed and the entire glomerulus is ischemic and appears to be 
hyalinized.7 Nodular lesions, exudative lesions, and mesangiolysis were simply shown 
as their presence or absence in each specimen.7 The severity of interstitial fibrosis and 
tubular atrophy (IFTA) and interstitial inflammation was scored according to the criteria 
of the Renal Pathology Society (RPS).16 The severity of IFTA was evaluated and graded 
on a scale from 0 to 3: grade 0, no IFTA; grade 1, <25%; grade 2, 25–50%; and grade 3, 
>50%.16 The severity of interstitial inflammation was evaluated and graded on a scale 
from 0 to 2: grade 0, absent; grade 1, infiltration only in relation to IFTA; and grade 2, 
infiltration in areas without IFTA.16 The severity of arteriolar hyalinosis was evaluated 
and graded on a scale from 0 to 3 as described previously: grade 0, normal appearance 
without PAS-positive deposits; grade 1, a light PAS-positive thickening is observed but 
at less than half the circumference of the arteriole in many arterioles; grade 2, most 
vessel walls are moderately thickened with PAS-positive deposition without apparent 
luminal narrowing; and grade 3, a heavy thickening of the majority of the vessel walls is 
seen with luminal narrowing or obliteration.7 The severity of arteriosclerosis was 
evaluated and graded on a scale from 0 to 2 according to the RPS criteria: grade 0, no 
intimal thickening; grade 1, intimal thickening less than the thickness of the media; and 
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grade 2, intimal thickening greater than the thickness of the media.16 Renal tissue 
specimens were examined by four nephrologists. 
 
Renal outcome 
The outcome for this study was end-stage renal disease (ESRD), which was defined as 
the need for dialysis or renal transplantation, as described elsewhere. 
 
Cells and cell culture 
The human renal tubular epithelial cell HK-2 was grown according to the 
manufacturer’s instructions (ATCC, CRL-2190, Manassas, VA). To examine the effect 
of purified IgG fractions with anti-EPOR antibodies on function of HK-2 cells under 
diabetic conditions, HK-2 cells were incubated with regulated concentrations of 
D-glucose (Wako chemicals Inc. Tokyo, Japan) and/or EPO. Briefly, HK-2 cells 
(3×105/ml) were cultured in DMEM supplemented with 0.5% heat-inactivated FBS 
(Gibco BRL) at 37℃ in a humidified atmosphere with 5%  CO2 for 24 h after the 
isolation in the presence of 5 or 20 mmol/l of D-glucose. Further, IgG fractions with 
anti-EPOR antibodies from patients were applied. HK-2 cells (1.5×105/ml) were 
preincubated with IgG (10 µg) in each culture medium for 60 min. Subsequently, 
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HK-2 cells were incubated in the presence of recombinant human EPO (10 ng/ml) 
(Thermo Fisher Scientific Inc., Yokohama, Kanagawa, Japan) for 48 h.  
 
RT-PCR 
The transcript of human EPOR was detected using reverse transcription-polymerase 
chain reaction (RT-PCR). In brief, total RNA was extracted from cultured HK-2 cells 
under normal or high concentration of glucose, and the complementary DNA (cDNA) 
was reverse-transcribed from 1μg total RNA using a RT-PCR kit (Takara Shuzo, Tokyo, 
Japan). The cDNA product was amplified by PCR as follows; incubation for three 
minutes at 94℃, followed by 35 cycles of one minute at 94℃, two minutes at 55℃, and 
three minutes at 72℃ and a final extension for seven minutes at 72℃ 17. Primers for 
human EPOR (sense, 5’-GCA-CCG-AGT-GTG-TGC-TGA-CGA-A-3’, antisense, 
5’-GGT-CAG-CAG-CAC-CAG-CAT-GAC-3’) were used to examine expression of 
human EPOR31. The human EPO-dependent cell line AS-E212, 18 was used as a positive 
control. The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was used for PCR controls19. 
 
Real-time quantitative PCR 
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To determine transcripts of MCP-1, total RNA was extracted from cultured HK-2 cells 
as described above. Quantitative real-time RT-PCR was performed on the ABI Prism 
7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). Assay IDs 




All comparisons between the two patient groups were performed using the chi-square 
test and Mann-Whitney’s U test. A renal outcome curve was obtained using the 
Kaplan-Meier method and compared by using the log-rank test. A multivariate Cox 
proportional hazards regression model was used to select factors that significantly 
affected the incidence of renal outcome and to estimate risk. The following variables 
were incorporated as covariates: age, sex, BMI, systolic blood pressure, proteinuria, 
eGFR, HbA1c, Hb, and the presence of anti-EPOR antibodies. A multiple comparison 
among three groups in in vitro experiments was performed using the Tukey’s test. All 
analyses were carried out using the statistical package SPSS, version 22 (SPSS, Tokyo, 
Japan) and the Stata 14.2 software (Stata Corporation, College Station, Tex., USA). 




Characteristics of the enrolled patients 
None of 112 patients enrolled had anti-GAD antibodies. The baseline 
characteristics of the 112 patients are shown in Table 1. Patients’ mean age was 62.9 
years, and 76 (67.9%) were male. The mean amount of urinary protein excretion was 
2.7 g/day. The mean serum creatinine concentration was 2.4 mg/dL, and the mean eGFR 
was 42.0 mL/min/1.73 m2. The median Hb concentration and reticulocyte count were 
11.2 g/dL and 4.4 × 104/mL, respectively. Diabetes-related parameters included a mean 
duration of 13.6 years at the time of work up on admission and a mean HbA1c of 6.7%. 
The mean levels of serum iron, TIBC, and ferritin were 71 mg/dL, 244 mg/dL, and 233 
ng/mL, respectively. The mean CRP level was 0.6 mg/dL.  
 
Clinical characteristics of type 2 diabetic patients with and without anti-EPOR 
antibodies 
Patients’ serum samples were analyzed by ELISA. Anti-EPOR antibodies 
were detected in 26 of the 112 patients. Demographic and clinical findings were 
compared between the patients with and without anti-EPOR antibodies; selected 
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findings are shown in Table 1. Patients with the antibodies were older than those 
without the antibodies (67.5 vs. 61.5 years, respectively). While the extent of 
proteinuria did not differ between both groups, renal function was significantly lower in 
the patients with the antibodies than in those without the antibodies, as indicated by the 
mean serum creatinine concentration and eGFR. In addition, the levels of total 
cholesterol and triglyceride were significantly decreased in the patients with anti-EPOR 
antibodies compared to those without the antibodies. The Hb level was significantly 
lower in the patients with anti-EPOR antibodies than in those without the antibodies, 
though the number of reticulocytes was not significantly different. ESAs were used 
more frequently in patients with the antibodies than those without (64 % vs. 19 %, p < 
0.01). No significant difference was found between the two groups for the other 
parameters examined, including duration of diabetes, HbA1c, systolic and diastolic 
blood pressure, HDL-cholesterol, iron, TIBC, ferritin, and CRP at the time of work up 
on admission and the use of ACE inhibitors or ARBs. 
 Stratified analysis of enrolled patients into 2 groups according to the baseline eGFR 
levels revealed that while mean baseline age as well as eGFR was similar in both groups, 
difference in BMI and Hb levels between patients with and without the antibodies was 
still observed in those with eGFR below 30 mL/min/1.73m2 (Supplementary Table 1). 
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In addition, ESA was more frequently used in patients with the antibodies than those 
without in this subpopulation (94% vs. 45%).  
 
Renal pathological characteristics of type 2 diabetic patients with anti-EPOR 
antibodies 
Renal biopsy findings were evaluated among the enrolled patients. Among the 
51 patients who had been diagnosed histologically with diabetic nephropathy, an 
interstitial inflammation score of 2 was observed more frequently in the patients with 
anti-EPOR antibodies than in those without the antibodies, while glomerular and 
vascular lesions were not significantly different between both groups (Table 2).  
 
Outcome of renal function  
Follow-up data were available for renal events in the enrolled 112 patients. 
The mean follow-up period was 45.3 ± 47.4 months during the study period. The 
event-free rate of renal events in the patients with anti-EPOR antibodies was 
significantly lower than in those without the antibodies (Figure 1). When stratified into 
2 groups according to the baseline eGFR, the difference was observed in patients with 
baseline eGFR below 30 mL/min/1.73m2, while it was not in those above 30 
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mL/min/1.73m2 (Supplementary Figure 1A and B). The difference in renal survival was 
also observed in patients with baseline eGFR below 60 mL/min/1.73m2, while there was 
a statistical difference in baseline eGFR (Supplementary Figure 2A and B, 
Supplementary Table 2). 
 
Clinical parameters associated with renal events 
The results of multivariate Cox proportional hazards regression analysis are 
shown in Table 3. The presence of anti-EPOR antibodies as well as high systolic blood 
pressure, proteinuria and eGFR were independent risk factors for ESRD. 
 
Effects of IgG fractions with anti-EPOR antibodies on the expression of monocyte 
chemoattractant protein (MCP)-1 mRNA in HK-2 cells under diabetic conditions 
The effect of purified IgG fractions with anti-EPOR antibodies on the expression of 
MCP-1 mRNA in HK-2 cells under a high glucose condition was examined in vitro. The 
expression of EPOR was confirmed by RT-PCR (Figure 2A). Administration of 10 
ng/mL EPO suppressed the high glucose-induced upregulation of MCP-1 mRNA 
(Figure 2B). Further, when compared with IgG purified from a healthy control, IgG 
from sera of diabetic patients positive for anti-EPOR antibodies in the presence of EPO 
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The present retrospective study demonstrated that serum anti-EPOR 
antibodies were detected in a subset of type 2 diabetic patients with CKD. 
Pathologically, the presence of antibodies was associated with increased interstitial 
inflammation. In addition, renal function declined more rapidly in patients with the 
antibodies than in those without the antibodies, and the presence of anti-EPOR 
antibodies was an additional risk factor for the progression of renal dysfunction.  
The present study revealed that anti-EPOR antibodies were present in 23% of 
type 2 diabetic patients with CKD who did not have anti-GAD antibodies. The presence 
of autoantibodies to self-proteins in type 2 diabetes has been suggested and reported 
previously. For example, 11 autoantibodies have been identified by the use of a 
high-density protein microarray among type 2 diabetic subjects in which the estimated 
prevalence was highest for autoantibodies to transaldolase 1 and mitochondrial 
ribosomal protein S7 (79% and 40%, respectively).20 In addition, autoantibodies to 
DNA-AGE21 and apolipoprotein A-122 and B-10023 have also been detected. Among 
these, anti-apolipoprotein A-1 autoantibodies were present in up to 36% of patients with 
type 2 diabetes and cardiovascular disease.22 Although the detailed pathogenic 
mechanisms underlying the development of autoantibodies remain to be investigated, 
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anti-EPOR antibodies may be additional autoantibodies that could be present in patients 
with type 2 diabetes and CKD. 
Anti-EPOR antibodies were pathologically associated with renal interstitial 
inflammation in type 2 diabetic patients with CKD. The interstitial cell infiltration 
observed in diabetic kidneys is an important pathological finding because of its impact 
on renal prognosis,7, 24 as is also found in other etiologies of CKD.25 Inflammatory 
interstitial infiltrates include T lymphocytes and macrophages.24, 25 These inflammatory 
cells, tubular epithelial cells, and vascular endothelial cells reportedly express EPOR, 
and the proliferation and activation of T lymphocytes were modulated by EPO 
administration in previous studies.26-29 In the present study, EPOR mRNA was detected 
in human proximal tubular cells, and EPO attenuated the expression of MCP-1 mRNA 
under high glucose conditions in vitro. In addition, IgG fraction with anti-EPOR 
antibodies in the presence of EPO upregulated the expression of MCP-1 mRNA. 
Whether binding of anti-EPOR antibodies to EPOR between these cells occurs in the 
kidney and whether the consequent nephrotoxicities are involved in the progression of 
renal damage via increased interstitial inflammation, even at areas without IFTA, 
remain to be investigated. However, anti-EPOR antibodies could be a useful biomarker 
for interstitial inflammation, which is associated with renal prognosis, in patients with 
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type 2 diabetes. 
The present study revealed that renal function in patients with anti-EPOR 
antibodies declined earlier than that in patients without the antibodies. Further, in 
multivariate analysis, the presence of anti-EPOR antibodies was selected as a significant 
risk factor for the decline of renal function. In this study, clinical parameters including 
higher proteinuria, and systolic blood pressure, together with lower renal function were 
confirmed as independent risk factors for ESRD in type 2 diabetic patients.7, 9, 10 In 
addition to the effect of anemia on the kidney, the present study and previous basic 
studies have demonstrated that EPOR is expressed by resident renal cells, including 
endothelial cells and tubular epithelial cells.28, 29 Previous studies demonstrated that 
EPO has renoprotective effects through suppression of inflammation, oxidative stress, 
and apoptosis of involved cells.30 On the basis of these non-erythropoietic activities of 
EPO, the presence of antibodies to EPOR was selected and considered as an 
independent explanatory factor from the levels of Hb in the present analysis. In the 
clinical setting, although clinical efficacy has yet to be validated, the administration of 
ESA to patients with CKD has the potential to preserve renal function, as suggested by 
previous clinical and epidemiological studies.31-33 The findings of these studies suggest 
that renal function may be exacerbated by the blockade of the EPO–EPOR interaction 
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via antibodies. Taken together, while the effect is relatively limited, anti-EPOR 
antibodies can serve as a serologic marker for the progression of renal injury in type 2 
diabetic patients with CKD in combination with other known parameters including 
albuminuria and proteinuria. 
We noted several limitations in the present study. First, this study was 
dependent on collectable medical records because of its retrospective design. Second, 
limiting study enrollment to only patients that were admitted to our tertiary medical care 
institution for work-up and treatment of an increased amount of proteinuria and/or 
kidney dysfunction during the course of diabetes, likely created a bias. Third, treatment 
contents were not evaluated fully. These limitations may have placed significant 
constraints on the interpretation of the results, particularly those related to differences in 
renal outcome. However, clinical examinations concomitant with renal biopsy samples 
in these patients are important for understanding the pathophysiology of type 2 diabetes 
and its clinical outcome. 
In conclusion, autoantibodies to EPOR may be involved in disease 
progression and may be a useful serologic marker for renal prognosis in type 2 diabetic 
patients with CKD. These potential biomarker could help physicians diagnose high-risk 
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Figure 1. Renal outcome of the retrospective analysis of 112 type 2 diabetic patients 
with chronic kidney disease. 
Event-free rate of end-stage renal disease (ESRD) stratified by the presence or absence 
of autoantibodies to the erythropoietin receptor (EPOR) according to the Kaplan-Meier 
method. Dotted line, anti-EPOR-negative (n = 86); solid line, anti-EPOR-positive (n = 
26). The mean follow-up period was 45.3 ± 47.4 months. Differences between the 
groups were compared using a log-rank test. 
 
Figure 2. Effect of EPO and IgG fractions with anti-EPOR antibodies on the expression 
of MCP-1 mRNA in HK-2 cells. 
(A) EPOR mRNA was assessed by RT-PCR. 5mMG: 5mM D-glucose, 20mMG: 20mM 
D-glucose, hEPOR: human erythropoietin receptor (B) Stimulation of HK-2 with 20mM 
D-glucose increased the expression of MCP-1 mRNA, and EPO decreased it (n = 3). 
5mM Glu: 5mM D-glucose, 20mM Glu: 20mM D-glucose, EPO: erythropoietin (C) 
Pretreatment with the IgG fraction from a patient with anti-EPOR antibodies under 
20mM glucose upregulate the expression of MCP-1 mRNA (n =3). 20mM Glu: 20mM 
 33 
D-glucose, EPO: erythropoietin, a-EPOR Ab: anti-erythropoietin receptor antibodies. 
All values are the mean ± SD. *P < 0.05. 
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Supplementary Figure 1. Renal outcome of type 2 diabetic patients according to 
baseline eGFR levels below and above 30 mL/min/1.73m2 
Event-free rate of ESRD stratified by the presence or absence of autoantibodies to the 
EPOR according to the Kaplan-Meier method. (A) Patients with baseline eGFR below 
30 mL/min/1.73m2. Dotted line, anti-EPOR-negative (n = 30); solid line, 
anti-EPOR-positive (n = 17). (B) Patients with baseline eGFR above 30 mL/min/1.73m2. 
Dotted line, anti-EPOR-negative (n = 56); solid line, anti-EPOR-positive (n = 9). 
Differences between the groups were compared using a log-rank test. 
 
Supplementary Figure 2. Renal outcome of type 2 diabetic patients according to 
baseline eGFR levels below and above 60 mL/min/1.73m2 
Event-free rate of ESRD stratified by the presence or absence of autoantibodies to the 
EPOR according to the Kaplan-Meier method. (A) Patients with baseline eGFR below 
60 mL/min/1.73m2. Dotted line, anti-EPOR-negative (n = 60); solid line, 
anti-EPOR-positive (n = 21). (B) Patients with baseline eGFR above 60 mL/min/1.73m2. 
Dotted line, anti-EPOR-negative (n = 26); solid line, anti-EPOR-positive (n = 5). 
Differences between the groups were compared using a log-rank test. 
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61.5 ± 12.3 67.5 ± 12.2     <0.05 
Proteinuria (g/day) 2.7 ± 3.1 2.7 ± 3.1 2.8 ± 3.1 0.9 




45.4 ± 30.2 30.7 ± 27.7 <0.05 
Duration of diabetes (years) 13.6 ± 9.8 13.1 ± 9.9 15.0 ± 9.7 0.41 
HbA1c (%) 6.7 ± 1.5 6.8 ± 1.6 6.4 ± 1.3 0.22 
BMI (kg/m2) 24.3 ± 4.0 24.7 ± 4.1 22.6 ± 3.3 <0.05 
SBP (mmHg) 136 ± 24 135 ± 23 137 ± 27 0.75 
DBP (mmHg) 74 ± 14 75 ± 14 72 ± 14 0.42 
T-Chol (mg/dL) 180 ± 51 186 ± 50 160 ± 47 <0.05 
HDL-C (mg/dL) 45 ± 18 47 ± 20 40 ± 12 0.12 
Triglyceride (mg/dL) 142 ± 79 152 ± 85 108 ± 39 <0.01 
Hemoglobin (g/dL) 11.2 ± 2.0 11.5 ± 2.0 10.1 ± 1.7 <0.01 




73.3 ± 43.2 66.3 ± 34.0 0.49 
TIBC (mg/dL) 244 ± 60 246 ± 65 239 ± 47 0.62 
Ferritin (ng/mL) 233 ± 226 227 ± 206 248 ± 274 0.71 
CRP (mg/dL) 0.6 ± 1.3 0.5 ± 1.2 0.9 ± 1.7 0.22 
Use of ACE inhibitors or ARBs 
(%) 
81 81 79 0.82 
Use of ESA (%) 30 19 64 <0.01 
*n = 73 
eGFR: estimated glomerular filtration rate; BMI: body mass index; SBP: systolic blood 
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pressure; DBP: diastolic blood pressure; T-Chol: total cholesterol; HDL-C: HDL cholesterol; 
TIBC: total iron binding capacity; CRP: C-reactive protein; ACE: angiotensin-converting 
enzyme; ARB: angiotensin II receptor blocker; ESA: erythropoiesis stimulating agent 










Diffuse lesions scale 3 or 4 24 (58.5) 3 (30.0) 0.16 
Nodular lesion 17 (41.5) 3 (30.0) 0.72 
Exudative lesion 17 (41.5) 3 (30.0) 0.72 
Mesangiolysis 16 (39.0) 3 (30.0) 0.73 




  score 0 5 (12.2) 0 (0.0) 
 
  score 1 28 (68.3) 4 (40.0) 
 
  score 2 8 (19.5) 6 (60.0) 
 
Arteriolar hyalinosis grade 2 or 
3 
8 (19.5) 5 (50.0) 0.10 
Arteriosclerosis score 2* 6 (17.6) 1 (16.7) 1 
*n = 34 in the anti-EPOR-negative group, n = 6 in the anti-EPOR-positive group 
EPOR: erythropoietin receptor; IFTA: interstitial fibrosis and tubular atrophy 
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Table 3. Parameters identified by multivariate Cox proportional hazards regression 
analysis associated with ESRD. 
 
  HR 95% CI P-value 
Age per -1 year 1.04  1.01-1.07 <0.05 
SBP per 1mmHg 1.04  1.02-1.06 <0.01 
Proteinuria per 1g/day 1.18  1.01-1.38 <0.05 
eGFR per -1 mL/min/1.73m2 1.05  1.02-1.07 <0.01 
Presence of anti-EPOR antibodies 2.78  1.20-6.43 <0.05 
 
SBP: systolic blood pressure; eGFR: estimated glomerular filtration rate; EPOR: 
erythropoietin receptor; HR: hazard ratio; CI: confidence interval 
HRs are adjusted for sex, age, body mass index, SBP, proteinuria, eGFR, HbA1c, 




Supplementary Table 1. Baseline characteristics of patients according to baseline eGFR 
levels below and above 30 mL/min/1.73m2 
 
eGFR < 30 mL/min/1.73m2 
 















Male 20 13 
 
38 5 
Age (years) 64.2 ± 12.8 67.8 ± 12.0     
 
60.1 ± 11.9 66.9 ± 13.1     
Proteinuria (g/day) 4.3 ± 3.9 3.4 ± 3.6 
 
1.7 ± 2.0 1.6 ± 1.4 
Serum creatinine （mg/dL） 4.1 ± 2.3 4.3 ± 2.3 
 
1.1 ± 0.4 1.0 ± 0.4 
eGFR （mL/min/1.73m2） 15.4 ± 7.8 15.0 ± 8.4 
 
61.5 ± 24.9 60.2 ± 27.5 
Duration of diabetes (years) 16.6 ± 11.8 14.7 ± 10.4 
 
11.3 ± 8.3 15.7 ± 8.2 
HbA1c (%) 6.3 ± 1.1 6.2 ± 1.4 
 
7.1 ± 1.7 6.8 ± 1.1 
BMI (kg/m2) 24.9 ± 4.3 22.2 ± 2.6* 
 
24.7 ± 4.1 23.4 ± 4.3 
SBP (mmHg) 137 ± 29 138 ± 30 
 
134 ± 19 135 ± 19 
DBP (mmHg) 72 ± 17 70 ± 16 
 
76 ± 12 76 ± 12 
T-Chol (mg/dL) 183 ± 56 153 ± 52 
 
188 ± 47 171 ± 35 
HDL-C (mg/dL) 47 ± 26 36 ± 10 
 
47 ± 15 47 ± 11 
Triglyceride (mg/dL) 160 ± 99 106 ± 42 
 
148 ± 77 112 ± 35 
Hemoglobin (g/dL) 10.4 ± 1.7 9.5 ± 0.9* 
 
12.1 ± 1.9 11.2 ± 2.2 
Reticulocytes（×104/μL） 4.5 ± 2.1 4.8 ± 2.9 
 
4.3 ± 2.0 3.2 ± 2.1 
Fe (mg/dL) 59 ± 35 61 ± 28 
 
87 ± 46 78 ± 45 
TIBC (mg/dL) 221 ± 70 230 ± 50 
 
271 ± 49 260 ± 35 
Ferritin (ng/mL) 249 ± 200 258 ± 320 
 
207 ± 213 227 ± 150 
CRP (mg/dL) 0.65 ± 1.20 1.07 ± 1.72 
 
0.53 ± 1.29 0.79 ± 1.87 





Use of ESA (%) 45 94**   6 11 
eGFR: estimated glomerular filtration rate; BMI: body mass index; SBP: systolic blood 
pressure; DBP: diastolic blood pressure; T-Chol: total cholesterol; HDL-C: HDL cholesterol; 
TIBC: total iron binding capacity; CRP: C-reactive protein; ACE: angiotensin-converting 
enzyme; ARB: angiotensin II receptor blocker; ESA: erythropoiesis stimulating agent 
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* p<0.05, ** p<0.01 
Supplementary Table 2. Baseline characteristics of patients according to baseline eGFR 
levels below and above 60 mL/min/1.73m2 
 
eGFR < 60 mL/min/1.73m2 
 















Male 43 15 
 
15 3 
Age (years) 61.6 ± 12.4 67.9 ± 12.0*  
 
61.3 ± 12.3 65.6 ± 14.0     
Proteinuria (g/day) 3.1 ± 3.3 3.1 ± 3.3 
 
1.6 ± 2.2 1.3 ± 1.3 
Serum creatinine （mg/dL） 2.7 ± 2.2 3.7 ± 2.3 
 
0.7 ± 0.2 0.7 ± 0.2 
eGFR （mL/min/1.73m2） 29.3 ± 16.7 19.0 ± 11.3* 
 
82.6 ± 19.5 80.0 ± 20.2 
Duration of diabetes (years) 14.6 ± 10.5 15.3 ± 9.7 
 
9.8 ± 7.2 13.0 ± 11.4 
HbA1c (%) 6.7 ± 1.5 6.4 ± 1.5 
 
7.1 ± 1.8 6.3 ± 0.5 
BMI (kg/m2) 24.9 ± 4.2 22.4 ± 2.3* 
 
24.4 ± 4.1 23.8 ± 6.0 
SBP (mmHg) 136 ± 25 136 ± 28 
 
133 ± 16 143 ± 21 
DBP (mmHg) 74 ± 15 71 ± 15 
 
76 ± 9 79 ± 10 
T-Chol (mg/dL) 183 ± 54 152 ± 48* 
 
194 ± 42 186 ± 35 
HDL-C (mg/dL) 46 ± 21 40 ± 13 
 
50 ± 17 42 ± 5 
Triglyceride (mg/dL) 160 ± 93 104 ± 40* 
 
135 ± 63 121 ± 34 
Hemoglobin (g/dL) 10.9 ± 1.8 9.8 ± 1.2** 
 
12.7 ± 1.9 11.2 ± 2.7 
Reticulocytes（×104/μL） 4.5 ± 2.2 4.8 ± 2.7 
 
4.0 ± 1.4 2.2 ± 1.6 
Fe (mg/dL) 69 ± 35 66 ± 36 
 
93 ± 68 66 ± 25 
TIBC (mg/dL) 244 ± 70 234 ± 50 
 
254 ± 34 261 ± 31 
Ferritin (ng/mL) 212 ± 174 235 ± 300 
 
288 ± 308 307 ± 105 
CRP (mg/dL) 0.56 ± 1.25 0.91 ± 1.60 
 
0.60 ± 1.30 1.20 ± 2.35 





Use of ESA (%) 26 80**   4 0 
eGFR: estimated glomerular filtration rate; BMI: body mass index; SBP: systolic blood 
pressure; DBP: diastolic blood pressure; T-Chol: total cholesterol; HDL-C: HDL cholesterol; 
TIBC: total iron binding capacity; CRP: C-reactive protein; ACE: angiotensin-converting 
 40 
enzyme; ARB: angiotensin II receptor blocker; ESA: erythropoiesis stimulating agent 
* p<0.05, ** p<0.01 
